The safety of drugs for OTC use: What evidence is required for an NSAID switch?

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 7, 2002, Pages 577-584

  MacDonald, Thomas M ^a   Beard, Keith ^b   Bruppacher, Rudolf ^c   Hasford, Joerg ^d   Lewis, Michael ^e   Logan, Richard F ^f   McNaughton, David ^a   Tubert Bitter, Pascale ^g   Van Ganse, Eric ^h   Moore, Nicholas ⁱ  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b VICTORIA INFIRMARY   (United Kingdom)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

^e EPES Epidemiology   (Germany)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g INSERM   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Analgesics; Equivalence; Gastrointestinal toxicity; NSAIDs; OTC; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CIMETIDINE; DICLOFENAC; IBUPROFEN; KETOCONAZOLE; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PSEUDOEPHEDRINE; RANITIDINE;

ACUTE KIDNEY FAILURE; ANALGESIA; ANALGESIC ACTIVITY; ANALGESIC NEPHROPATHY; ANAPHYLAXIS; ARTICLE; ASTHMA; BLEEDING DISORDER; COLITIS; CONGESTIVE HEART FAILURE; CONSULTATION; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; LIVER TOXICITY; MEDICAL EXPERT; OSTEOARTHRITIS; PAIN; PERIPHERAL EDEMA; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZATION; SAMPLE SIZE; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM; DOSE RESPONSE; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF MEDICATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, NON-PRESCRIPTION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SELF MEDICATION;

EID: 0036807540     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.736     Document Type: Article

References (35)

1. European Economic Community. Council Directive 92/26/ EEC of 31 March 1992 concerning the classification for the supply of medicinal products for human use. Official J 1992; L113: 103-106.
2. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001; 345: 810-816.
3. Sjoberg P. Safety assessment of OTC products-a regulatory view. Arch Toxicol Suppl 1995; 17: 341-345.
4. Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Varas-Lorenzo C. Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999; 19: 854-859.
5. Committee on Safety of Medicines. Relative safety of oral non-aspirin NSAIDs. Curr Prob Pharmacovigilance 1994; 20: 9-11.
6. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper GI toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-1337.
7. Evans JMM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency hospitalisation for colitis due to inflammatory bowel disease. Gut 1997; 40: 619-622.
8. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Pharmacol 1997; 44: 85-90.
9. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 2433-2439.
10. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572.
11. McMahon AD, Evans JMM, MacDonald TM. Hypersensitivity reactions associated with exposure to naproxen and ibuprofen: A cohort study. J Clin Epidemiol 2001; 54: 1271-1274.
12. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
13. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000; 160: 777-784.
14. Levy M. Adverse reactions to over-the-counter analgesics: an epidemiological evaluation. Agents Actions Suppl 1988; 25: 21-31.
15. Garcia Rodriguez LA, Jick H. Risk of upper GI bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-772.
16. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.
17. Henry D, Lim L, Garcia Rodriguez LA, et al. Variability in risk of GI complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
18. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997; 26(6 Suppl. 1): 16-20.
19. Strom BL, Schinar R, Bilker WB, Feldman H, Farrar JT, Carson JL. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med 1997; 157: 2626-2631.
20. Moore N, Van Ganse E, Le Parc J-M, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. Clin Drug Invest 1999; 18: 89-98.
21. Lesko SM, Mitchell A. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA 1995; 273: 929-933.
22. Jones B, Jarvis P, Lewis LA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-39.
23. Ferner U, Neumann N. Active control equivalence trials: some methodological aspects. Psychopharmacology 1992; 106: S93-S95.
24. International Conference on Harmonisation Expert Working Group. ICH Harmonised Tripartite Guideline-clinical safety data management: definitions and standards for expedited reporting, 1994.
25. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. Stat Med 1995; 14: 1659-1682.
26. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
27. Ebbutt AF, Frith L. Practical issues in equivalence trials. Stat Med 1998; 17: 1691-1701.
28. Tubert-Bitter P, Manfredi R, Lellouch J, Begaud B. Sample size calculations for risk equivalence testing in pharmacoepidemiology. J Clin Epidemiol 2000; 53: 1268-1274.
29. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-420.
30. Hasford J. Drug risk assessment: a case for large trials with leanprotocols. Pharmacoepidemiol Drug Safe 1994; 3: 321-327.
31. Senn S. Inherent difficulties with active control equivalence studies. Stat Med 1993; 12: 2367-2375.
32. ISPE. Guidelines for good epidemiology practices for drug, device, and vaccine research in the United States. Pharmacoepidemiol Drug Safe 1996; 5: 333-338.
33. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Safe 1998; 7: 275-280.
34. Bauer P. Multiple testing in clinical trials. Stat Med 1991; 10: 871-890.
35. Watson N, Nimmo WS, Christian J, Charlesworth A, Speight J, Miller K. Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. Int J Clin Pract 2000; 54: 686.